It is indicated for use in adults and pediatric patients (aged 9 months and older) for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients) due to Staphylococcus aureus or Streptococcus pyogenes. It is also effective to treat secondary bacterial skin infections like- - Infected dermatitis - Infected traumatic lesions (e.g. small lacerations, sutured wounds, cuts, abrasions etc.)
Retapamulin selectively inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial ribosome through an interaction that is different from that of other antibiotics. This binding site involves ribosomal protein L3 and is in the region of the ribosomal P-site and peptidyl transferase center. By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, block P-site interactions, and prevent the normal formation of active 50S ribosomal subunits. Retapamulin is bacteriostatic against Staphylococcus aureus and Streptococcus pyogenes at the Retapamulin in vitro minimum inhibitory concentration (MIC) for these organisms.
A thin layer should be applied to the affected area twice daily for 5 days. The treated area may be covered with a sterile bandage or gauze dressing if desired.
The effect of concurrent application of Retapamulin and other topical products to the same area of skin has not been studied.
In the event of sensitization or severe local irritation, usage should be discontinued. Not intended for ingestion or for oral, intranasal, ophthalmic or intravaginal use.
Application site irritation (Not more than 2% patients may experience)
Pregnancy category B. It is not known whether Retapamulin is excreted in human milk. Caution should be exercised when administered to a nursing woman.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)